End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
17.92 CNY | -0.78% | +0.67% | +7.11% |
Strengths
- The stock, which is currently worth 2024 to 0.28 times its sales, is clearly overvalued in comparison with peers.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The opinion of analysts covering the stock has improved over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+7.11% | 8.21B | B | ||
+14.53% | 69.68B | C+ | ||
-20.55% | 7.96B | B- | ||
-4.25% | 7.75B | C | ||
+2.08% | 4.64B | B- | ||
+17.12% | 4.32B | B+ | ||
-1.24% | 4.09B | B- | ||
-3.51% | 3.82B | B | ||
+21.42% | 3.62B | C+ | ||
+8.64% | 3.39B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 601607 Stock
- Ratings Shanghai Pharmaceuticals Holding Co., Ltd